164 related articles for article (PubMed ID: 36653728)
1. Model-Informed Approach Supporting Approval of Nexviazyme (Avalglucosidase Alfa-ngpt) in Pediatric Patients with Late-Onset Pompe Disease.
Li RJ; Ma L; Drozda K; Wang J; Punnoose AR; Jeng LJB; Maynard JW; Zhu H; Pacanowski M
AAPS J; 2023 Jan; 25(1):16. PubMed ID: 36653728
[TBL] [Abstract][Full Text] [Related]
2. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease.
Dimachkie MM; Barohn RJ; Byrne B; Goker-Alpan O; Kishnani PS; Ladha S; Laforêt P; Mengel KE; Peña LDM; Sacconi S; Straub V; Trivedi J; Van Damme P; van der Ploeg AT; Vissing J; Young P; Haack KA; Foster M; Gilbert JM; Miossec P; Vitse O; Zhou T; Schoser B;
Neurology; 2022 Aug; 99(5):e536-e548. PubMed ID: 35618441
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease.
Tiraboschi G; Marchionni D; Tuffal G; Fabre D; Martinez JM; Haack KA; Miossec P; Kittner B; Daba N; Hurbin F
J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):461-474. PubMed ID: 37535240
[TBL] [Abstract][Full Text] [Related]
4. Regulatory news: Avalglucosidase alfa-ngpt (Nexviazyme) for late-onset Pompe disease-FDA approval summary.
Punnoose AR; Jeng LJB; Maynard JW;
J Inherit Metab Dis; 2022 Nov; 45(6):1015-1017. PubMed ID: 35929375
[No Abstract] [Full Text] [Related]
5. Avalglucosidase alfa: First Approval.
Dhillon S
Drugs; 2021 Oct; 81(15):1803-1809. PubMed ID: 34591286
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic characterization of clinical skeletal muscle biopsy from late-onset Pompe patients.
Kinton S; Dufault MR; Zhang M; George K
Mol Genet Metab; 2023 Mar; 138(3):107526. PubMed ID: 36774918
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT;
Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.
Hahn SH; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Gambello MJ; Gibson JB; Hillman R; Stockton DW; Day JW; Wang RY; An Haack K; Shafi R; Sparks S; Zhao Y; Wilson C; Kishnani PS;
Genet Med; 2018 Oct; 20(10):1284-1294. PubMed ID: 29565424
[TBL] [Abstract][Full Text] [Related]
9. Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial.
Toscano A; Pollissard L; Msihid J; van der Beek N; Kishnani PS; Dimachkie MM; Berger KI; DasMahapatra P; Thibault N; Hamed A; Zhou T; Haack KA; Schoser B
Mol Genet Metab; 2024 Feb; 141(2):108121. PubMed ID: 38184428
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
Kishnani PS; Gibson JB; Gambello MJ; Hillman R; Stockton DW; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Day JW; Wang RY; Goldstein JL; An Haack K; Sparks SE; Zhao Y; Hahn SH;
Genet Med; 2019 Nov; 21(11):2543-2551. PubMed ID: 31086307
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J; Kishnani PS; Kushlaf H; Ladha S; Mozaffar T; Straub V; Toscano A; van der Ploeg AT; Berger KI; Clemens PR; Chien YH; Day JW; Illarioshkin S; Roberts M; Attarian S; Borges JL; Bouhour F; Choi YC; Erdem-Ozdamar S; Goker-Alpan O; Kostera-Pruszczyk A; Haack KA; Hug C; Huynh-Ba O; Johnson J; Thibault N; Zhou T; Dimachkie MM; Schoser B;
Lancet Neurol; 2021 Dec; 20(12):1012-1026. PubMed ID: 34800399
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Kishnani PS; Diaz-Manera J; Toscano A; Clemens PR; Ladha S; Berger KI; Kushlaf H; Straub V; Carvalho G; Mozaffar T; Roberts M; Attarian S; Chien YH; Choi YC; Day JW; Erdem-Ozdamar S; Illarioshkin S; Goker-Alpan O; Kostera-Pruszczyk A; van der Ploeg AT; An Haack K; Huynh-Ba O; Tammireddy S; Thibault N; Zhou T; Dimachkie MM; Schoser B;
JAMA Neurol; 2023 Jun; 80(6):558-567. PubMed ID: 37036722
[TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa.
Carter C; Boggs T; Case LE; Kishnani P
Front Genet; 2024; 15():1309146. PubMed ID: 38313679
[No Abstract] [Full Text] [Related]
14. Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study.
Tard C; Bouhour F; Michaud M; Beltran S; Fournier M; Demurger F; Lagrange E; Nollet S; Sacconi S; Noury JB; Magot A; Cintas P; Renard D; Deibener-Kaminsky J; Lefeuvre C; Davion JB; Salort-Campana E; Arrassi A; Taouagh N; Spinazzi M; ; Attarian S; Laforêt P
Eur J Neurol; 2024 Jul; 31(7):e16292. PubMed ID: 38587143
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report.
Kishnani PS; Kronn D; Brassier A; Broomfield A; Davison J; Hahn SH; Kumada S; Labarthe F; Ohki H; Pichard S; Prakalapakorn SG; Haack KA; Kittner B; Meng X; Sparks S; Wilson C; Zaher A; Chien YH;
Genet Med; 2023 Feb; 25(2):100328. PubMed ID: 36542086
[TBL] [Abstract][Full Text] [Related]
16. Evaluating avalglucosidase alfa for the management of late-onset Pompe disease.
Angelini C
Expert Rev Neurother; 2024 Mar; 24(3):259-266. PubMed ID: 38261315
[TBL] [Abstract][Full Text] [Related]
17. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
[TBL] [Abstract][Full Text] [Related]
18. The new horizons for treatment of Late-Onset Pompe Disease (LOPD).
Guémy C; Laforêt P
Rev Neurol (Paris); 2023; 179(1-2):81-89. PubMed ID: 36609019
[TBL] [Abstract][Full Text] [Related]
19. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
Schoser B; Stewart A; Kanters S; Hamed A; Jansen J; Chan K; Karamouzian M; Toscano A
J Neurol; 2017 Apr; 264(4):621-630. PubMed ID: 27372449
[TBL] [Abstract][Full Text] [Related]
20. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]